Tetrapeptides as potent protease inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase)

被引:34
作者
Johansson, A
Poliakov, A
Åkerblom, E
Lindeberg, G
Winwarter, S
Samuelsson, B
Danielson, UH
Hallberg, A
机构
[1] Univ Uppsala, Dept Med Chem, BMC, SE-75123 Uppsala, Sweden
[2] Univ Uppsala, Dept Biochem, BMC, SE-75123 Uppsala, Sweden
[3] Medivir AB, SE-14144 Huddinge, Sweden
关键词
D O I
10.1016/S0968-0896(02)00310-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A library of tetrapeptides,vas evaluated for Hepatitis C Virus NS3 protease inhibitor activity in an in vitro assay system comprising the native bifunctional full-length NS3 (protease-helicase, NTPase) protein. Tetrapeptides with K-i values in the high nanomolar range were identified, for example Suc-Chg-Glu-2-Nal-Cys (K-i = 0.27+/-0.03 muM) and Suc-Dif-Glu-Glu-Cys (K-i = 0.40+/-0.10 muM). Furthermore. it as shown that the inhibitory potencies Lire not affected significantly by assay ionic strength. As suggested by molecular modelling. potential binding interactions of the tetrapeptide inhibitors with the helicase domain might explain the data and structure-activity relationships thus obtained. Hence, we postulate that the full-length NS3 assay is a relevant system for inhibitor identification. offering new opportunities for inhibitor design. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3915 / 3922
页数:8
相关论文
共 48 条
[31]   α-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease [J].
Narjes, F ;
Brunetti, M ;
Colarusso, S ;
Gerlach, B ;
Koch, U ;
Biasiol, G ;
Fattori, D ;
De Francesco, R ;
Matassa, VG ;
Steinkühler, C .
BIOCHEMISTRY, 2000, 39 (07) :1849-1861
[32]   A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCVNS3 protease [J].
Narjes, F ;
Koehler, KF ;
Koch, U ;
Gerlach, B ;
Colarusso, S ;
Steinkuhler, C ;
Brunetti, M ;
Altamura, S ;
De Francesco, R ;
Matassa, VG .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (04) :701-704
[33]   Expression and purification of recombinant full-length NS3 protease-helicase from a new variant of Hepatitis C virus [J].
Poliakov, A ;
Hubatsch, I ;
Shuman, CF ;
Stenberg, G ;
Danielson, UH .
PROTEIN EXPRESSION AND PURIFICATION, 2002, 25 (03) :363-371
[34]   Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease [J].
Poupart, MA ;
Cameron, DR ;
Chabot, C ;
Ghiro, E ;
Goudreau, N ;
Goulet, S ;
Poirier, M ;
Tsantrizos, YS .
JOURNAL OF ORGANIC CHEMISTRY, 2001, 66 (14) :4743-4751
[35]   1-aminocyclopropaneboronic acid: Synthesis and incorporation into an inhibitor of hepatitis C virus NS3 protease [J].
Priestley, ES ;
Decicco, CP .
ORGANIC LETTERS, 2000, 2 (20) :3095-3097
[36]   Recent advances in the molecular biology of Hepatitis C virus [J].
Rosenberg, S .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 313 (03) :451-464
[37]   Product inhibition of the hepatitis C virus NS3 protease [J].
Steinkühler, C ;
Biasiol, G ;
Brunetti, M ;
Urbani, A ;
Koch, U ;
Cortese, R ;
Pessi, A ;
De Francesco, R .
BIOCHEMISTRY, 1998, 37 (25) :8899-8905
[38]  
Steinkuhler C, 1996, J VIROL, V70, P6694
[39]   Hepatitis C virus serine protease inhibitors:: Current progress and future challenges [J].
Steinkühler, C ;
Koch, U ;
Narjes, F ;
Matassa, VG .
CURRENT MEDICINAL CHEMISTRY, 2001, 8 (08) :919-932
[40]   SEMIANALYTICAL TREATMENT OF SOLVATION FOR MOLECULAR MECHANICS AND DYNAMICS [J].
STILL, WC ;
TEMPCZYK, A ;
HAWLEY, RC ;
HENDRICKSON, T .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1990, 112 (16) :6127-6129